Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to…

2023 was a great year of progress for NeoPhore. At AACR-NCI-EORTC in Boston in October, the first disclosure of lead compound NP1867 was presented. This demonstrated that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples. 2023 was a great year of progress for NeoPhore. At AACR-NCI-EORTC inBostonin October, the first disclosure of lead compound NP1867 was presented. This demonstrated that NP1867 functionally...

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics…

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammationNewly appointed CEO, Dr Xavier Leroy, will lead GIO Therapeutics in advancing groundbreaking research on GPCR-targeted drugs for oncology and inflammatory diseasesDr Tilly Bingham, appointed CSO/COO, is also selected from the Cumulus team to spearhead the drug development initiatives at GIO TherapeuticsEdinburgh, Scotland, 1...

EMA Aesthetics Announces a Long-Term Strategic and Equity Partnership with ROHTO…

This strategic alliance signals ROHTO's acceleration into the medical aesthetics sector, supporting the growth of EMA Aesthetics in a rapidly expanding global market. EMA and ROHTO will employ R&D and collaboration to jointly develop existing and novel aesthetic products. This partnership provides ROHTO with a gateway into the aesthetics industry beyond Japan, emphasizing their commitment to harness the notable expansion in the aesthetics sectors within the EU and US, into 2024 and beyond…

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene…

CTX is a rare autosomal recessive genetic disorder that affects the body's ability to metabolize fats known as cholesterols. Patients with CTX are unable to break down different forms of cholesterol, which build up in certain areas of the body and are characterized by fatty yellow nodules (tendon xanthomas) located in the connective tissues within the brain. These deposits can cause progressive damage to the brain and other areas of the body. Disease symptomatology is characterized by chronic…

Implantica's RefluxStop™ featured in seven presentations accepted at the largest…

Dr. Peter Forsell, CEO of Implantica, says, "It's a humbling distinction to have RefluxStop™ included in seven scientific research abstracts that will be presented at SAGES, the biggest GI surgeon meeting in the US. It speaks volumes about the rapidly growing interest from top surgeons in RefluxStop™'s unique way of treating GERD. We're grateful these independent surgeons are committed to evaluating and reporting the impact that RefluxStop™ and surgical GERD treatment can have on…

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of…

U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File CASTRES,Franceand THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre...

Legacy Novozymes delivers solid last full-year results

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.COPENHAGEN, Denmark – February 1, 2024.In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin...

Results update for 2023 – unaudited

6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation As Novozymes just closed the combination with Chr. Hansen on January 29, and the annual report now is expected to be released on February 8, this announcement only contains unaudited numbers. Full audited financial statements as well as non-financial numbers will be released with the annual report on February 8. This result update allows us to provide selected numbers for Novozymes...

Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst…

Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline Paris, February 1, 2024Q4 2023 sales growth of 9.3% at CER and business EPS (1)increase of 8.2% at CERSpecialty Care grew 13.7% driven by Dupixent and ALTUVIIIO launch performance, more than offsetting competition from generics of Aubagio in all key marketsVaccines sales increased strongly (up 21.1%) mainly as a result of the unprecedented...

Press Release: François-Xavier Roger appointed Chief Financial Officer, member…

François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive CommitteeParis, February 1, 2024. François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi's Executive Committee effective April 1, 2024. He will be based in Paris and will succeed Jean-Baptiste Chasseloup de Chatillon who will step down from his role to become Head ofApprentis d'Auteuil.Apprentis d'Auteuilis a foundation that supports adolescents who are...

Sandoz announces changes in the Board of Directors

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEGraeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General MeetingFrançois-Xavier Roger announced to pursue a new executive responsibility and therefore to step down from the Sandoz Board of Directors post publication of the financial statements 2023Basel, February 1, 2024- The Board of Directors of Sandoz announced today that it proposes...

New long-term data for Roche's Vabysmo show sustained retinal drying and vision…

Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DME Basel, 1 February 2024 -...

NX Netherlands Receives IATA CEIV Pharma Certification for Its Warehouse Near…

Exterior view of warehouse: https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202401295862/_prw_PI2fl_K8ND1iwS.jpg Exterior view of warehouse:https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202401295862/_prw_PI2fl_K8ND1iwS.jpg Interior view of CEIV Pharma-certified warehouse:https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202401295862/_prw_PI3fl_slVnxK8s.jpg The Netherlandsis home to a cluster of some of the most advanced biotechnology companies inEurope,...

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves…

Group salesgrow by 1% 1at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group salesincrease by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple...

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

PARIS and CAMBRIDGE, Mass., Jan.31, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6 thAnnual Biotechnology...

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. As previously announced, the transfer includes the entire Jyseleca® business, including the European and UK Marketing Authorizations, and the commercial, medical affairs and development activities for Jyseleca®. In connection with the completion of the transaction,...

Immune Health Supplements Market Pioneers Next-Gen Wellness Solutions, More than…

Browse in-depth TOC on the Immune Health Supplements Market Browse in-depth TOC on the Immune Health Supplements Market 335 – Pages 166 - Tables 156 - Figures Immune Health Supplements Market Report Scope • Increasing Potential Consumer Population with Chronic Illness Market Trend & Opportunity Rising Preference for Gummies, Soft Gels, & Effervescent Based Immune Supplements The COVID-19 pandemic significantly drove the uptake...

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™…

The REDUCED-1 Study had two enrollment cohorts that were conducted under an identical protocol in the United States and in Israel. Twenty-five patients were enrolled in the U.S. and 15 patients were enrolled in Israel. All patients (N=40) are now in the follow-up phase of the study where primary efficacy (change in daytime systolic ambulatory blood pressure) will be analysed at 3 months and safety will be analysed at 1 month and 12 months follow-up respectively. The REDUCED-1 Study had two...

Spinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive…

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4305 Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4305 Market Trends Launch of new therapeutics for spinal cord injury with supporting rehabilitation centers is one of the major trends in the global spinal cord injury therapeutics market. Spinal cord injury therapeutics is advancing with the continuous technological development in...

The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing…

Evaxion Biotech Announces Pricing of $15 Million Public Offering

ITM Obtains Manufacturing License in the U.S.

Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

SK chemicals Targets the US Medical Packaging Market with Circular Recycling…

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to…

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics…

EMA Aesthetics Announces a Long-Term Strategic and Equity Partnership with ROHTO…

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene…

Implantica's RefluxStop™ featured in seven presentations accepted at the largest…

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of…

Legacy Novozymes delivers solid last full-year results

Results update for 2023 – unaudited

Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst…

Press Release: François-Xavier Roger appointed Chief Financial Officer, member…

Sandoz announces changes in the Board of Directors

New long-term data for Roche's Vabysmo show sustained retinal drying and vision…

NX Netherlands Receives IATA CEIV Pharma Certification for Its Warehouse Near…

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves…

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Immune Health Supplements Market Pioneers Next-Gen Wellness Solutions, More than…

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™…

Spinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive…